---
layout: post
title: "罗欣药业替戈拉生片获准开展新适应症临床试验"
date: 2022-03-06 18:39:48 +0800
categories: shanghaizhengquanbao·zhongguozhengquanwang
tags: 上海证券报·中国证券网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002793" data-code="002793|0|2" data-code2="002793|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002793&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002793_0" data-code="K 002793|0|2" data-code2="K 002793|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>罗欣药业公告，公司下属子公司山东罗欣收到国家药品监督管理局下发的替戈拉生片幽门螺杆菌感染适应症的《药物临床试验批准通知书》。本次获准开展临床试验的适应症为与适当的抗菌疗法联用根除成人幽门螺杆菌感染。<br /></p><p class="em_media">（文章来源：上海证券报·中国证券网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203062298097212>

[返回上海证券报·中国证券网新闻](//finews.withounder.com/category/shanghaizhengquanbao·zhongguozhengquanwang.html)｜[返回首页](//finews.withounder.com/)